Life Transitions

"The FDA did not raise any concern regarding the general approvability of elinzanetant in its correspondence," according to an anouncement from Bayer.

New research suggests oxytocin could help reduce mood disturbances caused by sleep disruption during menopause and postpartum.

Experts urge the FDA to update outdated warnings on menopausal hormone therapies, emphasizing the safety and benefits of low-dose vaginal estrogen.

Nearly one-third of women with premature ovarian insufficiency experience depressive symptoms, according to a recent study.

A low-fat, soy-rich vegan diet significantly decreases severe hot flashes and supports healthy weight loss, according to new research.

A new study reveals that emotional symptoms such as anger and feeling out of control intensify before menstruation and become more severe during the menopause transition.

In this Q&A, Karyn S. Eilber, MD, shares some of the biggest takeaways from the new AUA/SUFU/AUGS 2025 Guidelines on Genitourinary Syndrome of Menopause.

Angie Lee, MD, FACOG, discusses how clinicians can bridge the gap in menopause care to ensure better outcomes for their patients.

A meta-analysis presented at 2025 ACOG Annual Clinical & Scientific Meeting found that elinzanetant demonstrated a reduction in VMS frequency and intensity.

New research reveals that maintaining healthy blood iron levels may improve cognitive performance and reduce brain fog in women during the menopausal transition.

New guidelines on GSM recommends symptom-based diagnosis, shared decision-making, and local estrogen as first-line therapy to improve quality of life.

A new study finds that women who experience menopause before the age of 40 years face a higher risk of cognitive decline.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

The study is among the first to examine dietary patterns relating to overall healthy aging rather than specific diseases or mortality.

A recent study from researchers at the University of Calgary found that a higher frequency of menopausal symptoms i linked to poorer cognitive function and behavioral impairments

Many women experience perimenopause symptoms in their 30s, but most delay treatment. Early awareness can improve care and quality of life.

A new study highlights the anti-aging properties of key hormones, offering potential treatments for wrinkles, hair graying, and other signs of aging.

A large-scale study confirms that hormone therapy does not increase the risk of glioma, offering reassurance to postmenopausal women considering treatment.

A recent study highlights worsened walking and motor skills in postmenopausal women with multiple sclerosis, shedding light on the need to determine hormone therapy benefits.

A recent study highlights improved sexual function and reduced distress among nonheterosexual women during menopause compared to their heterosexual counterparts, shedding light on how sexual identity impacts well-being.

The FDA has added a boxed warning for fezolinetant (VEOZAH; Astellas), highlighting the rare occurrence of serious liver injury in patients taking the menopause treatment.

Weak handgrip strength may predict diabetes risk in postmenopausal women, highlighting the importance of muscle strength in diabetes prevention.

Advances in reproductive technology are making pregnancies over the age of 50 years possible, but they come with unique challenges, requiring tailored prenatal and postpartum care.

In a recent study, an inverse relationship was discovered between anti-Müllerian hormone levels and early menopause, highlighting the need to develop interventions for fertility preservation based on genetics.

In a recent study, menopausal women with frequent and time-consistent vasomotor symptoms were more likely to develop diabetes than those with reduced vasomotor symptoms.

The New Drug Application (NDA) acceptance is supported by positive data from 3 clinical trials (OASIS 1, 2, and 3).

In a recent study, patients with early puberty had increased rates of diabetes, obesity, and other metabolic conditions, as well as increased mental health risks.

PH80 nasal spray shows promise in reducing menopausal hot flashes, offering an effective and safe non-hormonal treatment option.

At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.